Literature DB >> 11302983

National Institute for Clinical Excellence guidance: too NICE to glycoprotein IIb/IIIa inhibitors?

C J Knight.   

Abstract

Mesh:

Substances:

Year:  2001        PMID: 11302983      PMCID: PMC1729715          DOI: 10.1136/heart.85.5.481

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  7 in total

1.  Docetaxel induced cardiotoxicity.

Authors:  M Shimoyama; Y Murata; K I Sumi; R Hamazoe; I Komuro
Journal:  Heart       Date:  2001-08       Impact factor: 5.994

2.  Strong prognostic value of combining N-terminal atrial natriuretic peptide and ECG to predict death in heart patients from general practice.

Authors:  O W Nielsen; J Hilden; J F Hansen
Journal:  Heart       Date:  2001-08       Impact factor: 5.994

3.  Implementation of the NICE guidelines for the primary prevention of mortality from ventricular tachyarrhythmias: implications for UK electrophysiology centres; activity modelling from the UK-HEART study.

Authors:  N P Gall; M T Kearney; A Zaman; S O'Nunain; K A Fox; A Flapan; J Nolan
Journal:  Heart       Date:  2001-08       Impact factor: 5.994

4.  Renin angiotensin system inhibition is associated with reduced free radical concentrations in arteries of patients with coronary heart disease.

Authors:  C Berry; N Anderson; A J Kirk; A F Dominiczak; J J McMurray
Journal:  Heart       Date:  2001-08       Impact factor: 5.994

5.  Same day discharge following elective percutaneous coronary intervention in patients with stable angina.

Authors:  A P Banning; O J M Ormerod; K Channon; C J McKenna; W Orr; B Boulton; Y Bashir; J C Forfar
Journal:  Heart       Date:  2003-06       Impact factor: 5.994

Review 6.  Heparin dose during percutaneous coronary intervention: how low dare we go?

Authors:  G Niccoli; A P Banning
Journal:  Heart       Date:  2002-10       Impact factor: 5.994

7.  Learning on the Web. Case 3: acute chest pain.

Authors:  Christopher S R Baker
Journal:  Heart       Date:  2004-01       Impact factor: 5.994

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.